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The battle against HIV is beingwaged onmany fronts, fromprevention efforts to the development of
new antiviral therapies. Although the body’s immune system is ultimately overcome if an infection is
left untreated, there are numerous lines of host defense that, when augmented, could counter HIV’s
relentless assault. This Select highlights recent advances in understanding the interplay between
HIV and host cells.The HIV drug maraviroc (orange) locks CCR5
(blue) in an inactive conformation. Image cour-
tesy of B. Wu.Putting CCR5 on Lockdown
HIV targets CD4-positive immune cells, and some strains require the chemo-
kine receptor CCR5 as a coreceptor. Maraviroc is an HIV inhibitor that func-
tions by binding to CCR5 to prevent viral entry into immune cells. Tan et al.
(2013) now present a crystal structure of CCR5 bound to maraviroc at
2.7 A˚, which reveals insights into its molecular mechanisms of action that
may guide future structure-based drug design. The drug binds deep within
the extracellular pocket of CCR5, and comparison of the maraviroc-
CCR5 complex with existing structures of CXCR4, a related protein that
acts as a coreceptor for other HIV strains, reveals that the drug’s binding
region is distinct from where either CCR5’s chemokine ligands or the viral
glycoprotein gp120 bind. The
binding region is shown bio-
chemically to be important for
receptor activation, but not for
recognition with chemokines,
consistent with previous work
indicating that maraviroc stabi-
lizes CCR5 in an inactive con-
firmation. Future work may usethis guidance to develop additional inhibitors of CCR5 or perhaps of
CXCR4, especially given that none of the currently approved HIV entry inhib-
itors are directed at CXCR4.
Tan, Q., et al. (2013). Science 341, 1387–1390.Reverse-transcribed HIV cDNA binds to and
activates cGAS, which produces the second
messenger cGAMP toactivateSTINGand trigger
innate immune responses. Figure courtesy of
D. Gao.cGAS Fuels the Antiviral Response
Recent work has established that cGAS (cyclic guanosine monophosphate-
adenosine monophosphatase synthase) is a critical innate immune sensor
of cytoplasmic DNA. cGAS produces cyclic GMP-AMP (cGAMP), which
binds and activates STING, leading to production of type I interferons.
Recent efforts by Gao et al. (2013) establish that cGAS is not only an
essential element of the host responses to DNA viruses, such as herpes
and vaccinia viruses, but also to retroviruses that use RNA for their genetic
material. They show that cDNA from reverse-transcribed HIV RNA triggers
the same signaling cascade as DNA viruses, culminating in interferon b
induction, and further show that cGAS is essential for innate immune
responses to simian immunodeficiency virus and murine leukemia virus, sug-
gesting that this pathway is broadly relevant. This pathway is usually not
triggered in the primary cells infected by HIV, CD4-positive T cells, and
macrophages due to the presence of host factors that prevent the accumu-
lation of cytosolic DNA. The therapeutic opportunity raised by this work
and suggested by the authors would be the augmentation of host cyclic
GMP-AMP to overcome this block, sound the alarm, and eliminate infected
cells.
Gao, D., et al. (2013). Science 341, 903–906.Cell 155, October 24, 2013 ª2013 Elsevier Inc. 487
Some interferon-stimulated genes (ISGs) inhibit
HIVDNA (blue) synthesis, andMX2 (orange) pre-
vents its nuclear accumulation. Figure courtesy
of M. Malim.Dismantling HIV’s Nuclear Arsenal
Although ultimately outmatched, cells are not defenseless against HIV’s
attacks. Type I interferons, made in response to HIV infection, promote the
expression of proteins called restriction factors that counter viral replication.
There are only a few known restriction factors for HIV, and in an effort to add
to this short list, Goujon et al. (2013) employ a combination of ectopic expres-
sion and gene silencing to identify new candidate host factors. From this
screen, the authors show that MX2 (myxovirus resistance 2), a protein with
homology to the GTPase dynamin, disrupts the accumulation of reverse-
transcribed HIV in the nucleus and its integration into the genome. These find-
ings raise many interesting questions regarding MX2’s mechanism of action,
and the study offers some tantalizing clues and starting points for future
work. First, the authors establish that it is the viral Capsid protein that confers
HIV’s susceptibility to MX2. Second, the authors suggest that MX2’s GTPaseactivity is not required for its effects. This stands in contrast to MX1, a closely related protein that is known to inhibit a broad
range of viruses, including influenza (though interestingly not HIV); blocking the ability of MX1 to hydrolyze GTP completely
suppresses its effect on influenza. Future efforts may reveal the cell-biological functions of MX2, perhaps in membrane
trafficking, and how these are connected to its impact on HIV replication.
Goujon, C., et al. (2013). Nature. Published online September 18, 2013. http://dx.doi.org/10.1038/nature12542.Moving from Containment to Eradication
With HIV treatments increasingly successful in controlling established infections, what are the prospects for eliminating the
virus from infected individuals? Working with highly pathogenic SIV infection in rhesus macaques, Hansen et al. (2013)
show that vaccination with a cytomegalovirus engineered to express SIV protein is not only able to control the infection
but is also, over time, able to reduce it to an undetectable level via sustained immune surveillance. The most striking proof
for complete or nearly complete elimination of SIV comes from experiments in which 60 million blood cells are transferred
from an exposed but vaccinated macaque to an unexposed individual, which fails to lead to SIV infection. Their findings build
on their prior demonstration that this vaccination strategy can curtail early stage infection through an effector memory T cell
response. The new work, if applicable to HIV, might foreshadow not only the development of a long-hoped-for effective HIV
vaccine, but also a broadening of its potential benefits to include those with well-established infections.
Hansen, S.G., et al. (2013). Nature. Published online September 11, 2013. http://dx.doi.org/10.1038/nature12519.
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